X4 Pharmaceuticals Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
X4 Pharmaceuticals (XFOR) PT Lowered to $10 at Stifel
March 17, 2022 12:43 PM EDTStifel analyst Stephen Willey lowered the price target on X4 Pharmaceuticals (NASDAQ: XFOR) to $10.00 (from $18.00) while maintaining a Buy rating.
... MoreX4 Pharmaceuticals (XFOR) Misses Q4 EPS by 56c
March 17, 2022 6:08 AM EDTX4 Pharmaceuticals (NASDAQ: XFOR) reported Q4 EPS of ($1.24), $0.56 worse than the analyst estimate of ($0.68). Revenue for the quarter came in at $0 , versus $0 reported last year.
For earnings history and earnings-related data on X4 Pharmaceuticals (XFOR) click here.
... More